Drug Profile
Research programme: beta catenin inhibitors - Clinical Data
Alternative Names: 316; ATL 316; AV-65; AVB-08; AVB-63; AVB-92; AVN316; LC 363; LC-363 compoundsLatest Information Update: 27 Apr 2012
Price :
$50
*
At a glance
- Originator Avalon Pharmaceuticals
- Developer Clinical Data
- Class Small molecules
- Mechanism of Action Beta catenin inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Apr 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
- 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
- 08 Dec 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009) ,